Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Formulary Coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentPriority HealthPolicy N/A

    Priority Health Medicare 2026 Formulary (Drug List) - Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 formulary (drug list) for Priority Health Medicare, describing covered drugs, applicable restrictions (prior authorization, quantity limits, step therapy), member rights to exceptions and transitions, and how to use the formulary. It affects plan members, prescribers, and network pharmacies using Priority Health Medicare benefits.

    Policy Summary
    PayerPriority Health
    PolicyPriority Health Medicare 2026 Formulary (Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeFormulary maintenance (no material change)
    Effective DateJun 1, 2026
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting documentation when a drug is marked PA, and follow listed QL or ST requirements to avoid coverage denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026formulary year
    Jun 1current as of
    30 daystransition supply
    72 hrsexception decision time
    PA/QL/STrequirement flags

    Formulary Coverage & Requirements

    General formulary coverage and exception process

    Covered when plan rules and any listed requirements/limits are met.

    Formulary coverage conditions: Drug is listed on the Priority Health Medicare formulary and is medically necessary, the prescription is filled at a Priority Health Medicare network pharmacy, and other plan rules are followed.

    [[chunk 3]]

    Utilization management that may apply: Prior authorization (PA), quantity limits (QL), or step therapy (ST) may apply to specific drugs as noted in the formulary Requirements/Limits column.

    [[chunk 12]]

    Formulary exception (tiering/coverage): An exception (formulary or tiering) may be approved only when the prescriber documents that alternative formulary drugs or applying the restriction would not be as effective or would cause harm; prescriber must provide supporting medical reasons.Decision within 72 hours (24 hours expedited)
    Policy Summary
    PayerPriority Health
    PolicyPriority Health Medicare 2026 Formulary (Drug List) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeFormulary maintenance (no material change)
    Effective DateJun 1, 2026
    Last ReviewMay 21, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting documentation when a drug is marked PA, and follow listed QL or ST requirements to avoid coverage denial.
    SourceLink
    On This Page
    Formulary Coverage & RequirementsFormulary Listings & Coding / Quantity ExamplesPrescriber Requirements, Prior Authorization & Step TherapyPer-Drug Quantity Limits (Selected Examples)Home Infusion, Infusion Center & Billing (Part B vs D)Abbreviations, Tier Definitions & TermsTransition and Continuation RulesStep Therapy Rules & ExamplesBackground & Policy Scope

    [[chunk 14]]

    Transition/temporary coverage: While an exception or change is pending (or when first joining the plan), members may receive a temporary/transition supply per plan rules (at least 30 days; 31 days emergency for LTC residents).30 days (or 31 days for long-term care emergency)

    [[chunk 15]]

    Formulary coverage with requirements

    Coverage depends on tier and any listed requirements/limits; specific drugs require PA, QL, ST, or are HI-designated.

    Tier-based coverage: A drug is covered according to its assigned formulary tier (T1–T5); tier assignment affects cost-sharing and supply limits (Tier 5 = specialty, 30-day supply only).

    [[chunk 59]] [[chunk 71]]

    Requirement flags: If a drug entry includes flags (PA, QL, ST, HI, LA, NE, B/D) the corresponding requirement must be satisfied for coverage (examples shown in formulary lines).

    [[chunk 63]] [[chunk 72]]

    Provider responsibilities: When PA, ST or QL is listed the provider must submit the applicable prior authorization or documentation, or ensure the prescription does not exceed the listed quantity limits to obtain coverage.

    [[chunk 12]]

    General coverage approach for listed drugs

    Coverage follows formulary tier assignment with utilization controls as listed; drugs with PA/ST/QL have restrictions.

    Coverage determination depends on drug tier and meeting any listed utilization management requirements (PA, ST, QL).

    Providers must follow PA/ST/QL listed for each product (see formulary entries).

    Supply and limit rules: Quantity limits are enforced per product (examples: EA or ML per specified days) and Tier 5 specialty drugs are limited to a 30-day supply.see per-drug QL entries

    [[chunk 59]] [[chunk 71]]

    Denial risk if not followed: Claims for drugs marked PA/ST/QL may be denied if the associated prior authorization or step requirements are not completed or if quantity limits are exceeded.

    [[chunk 12]] [[chunk 59]]

    Formulary coverage entries (per-drug)

    Coverage and utilization management per drug as listed (examples below).

    Example: MOUNJARO: MOUNJARO subcutaneous solution auto-injector is listed with Requirements = PA; QL (2 ML per 28 days).QL 2 ML per 28 days

    [[chunk 137]]

    Example: OZEMPIC: OZEMPIC products are listed with Requirements = PA; QL (3 ML per 28 days) for listed pen formulations.QL 3 ML per 28 days

    [[chunk 137]] [[chunk 138]]

    Example: RYBELSUS: RYBELSUS is listed with Requirements = PA; QL (30 EA per 30 days).QL 30 EA per 30 days

    [[chunk 138]]

    Example: PAXLOVID: PAXLOVID formulations have quantity limits that vary by package (examples: QL 40 EA per 180 days; QL 22 EA per 180 days; QL 60 EA per 180 days).varies by formulation

    [[chunk 132]]

    Example: EMTRIVA / EFAVIRENZ: EMTRIVA oral solution and efavirenz oral tablet are listed with their respective tiers and any QL noted in the formulary lines.

    [[chunk 126]] [[chunk 128]]

    Formulary listing and administrative controls

    Coverage is determined by formulary tier and the listed requirements/limits for each product.

    Tier + requirement entry: Each formulary line shows an assigned tier (T1–T5) and may include requirement flags such as PA, QL, B/D, HI, ST or LA; coverage is subject to satisfying those flags.

    [[chunk 144]] [[chunk 150]]

    Tier 5 specialty rule: Drugs assigned to Tier 5 (Specialty) are limited to a 30-day supply and often require PA and QL enforcement.30-day supply limit

    [[chunk 59]] [[chunk 144]]

    Coverage controls (PA/QL/HI) and formulary tiering

    Coverage and use constraints for listed drugs are indicated by tier assignments and specific controls; coverage is subject to PA, QL, HI, or other plan rules as annotated below.

    Formulary inclusion: Drugs listed in the formulary are included for coverage but may carry additional requirements or limits shown in the Requirements/Limits column.

    [[chunk 162]]

    Prior authorization required: If a drug is annotated with 'PA' (examples: REPATHA, NEXLETOL, NEXLIZET, ENTRESTO, etc.), prior authorization must be obtained before coverage is approved.

    [[chunk 175]]

    Quantity limits enforced: Drugs annotated with 'QL' have maximum quantities per period (examples include EA or ML limits) and claims exceeding these limits will require justification or authorization.see per-drug QL entries

    [[chunk 173]]

    Home infusion / site-of-care (HI): Products marked 'HI' may require home infusion authorization or may be billed under the medical benefit; site-of-care designation affects authorization routing.

    [[chunk 171]]

    General coverage by tier

    Coverage is determined by formulary tier and any listed requirements/limits.

    Tier assignment effects: Formulary tier assignment (T1–T5) determines preferred status and member cost-sharing; specialty tier (T5) drugs have supply restrictions and frequently require utilization management.

    [[chunk 199]]

    PA / QL constrained coverage

    Prior authorization and quantity limits apply to specific agents.

    PA or QL flagged drugs: Drugs marked 'PA' require prior authorization and drugs marked 'QL' are subject to the specified quantity limits; examples include tolvaptan (PA; QL 120 EA/30 days) and FASENRA (QL 0.5 ML/30 days).

    [[chunk 199]] [[chunk 211]]

    Formulary tiering and requirement flags

    Coverage and requirement indicators shown per drug

    Tier assignment and requirement flags: Each listed drug has an associated tier (T1–T5) and may include requirement flags (PA, QL, LA, B/D, NE, HI); coverage approval depends on satisfying any PA/ST/QL conditions shown in the line item.

    [[chunk 216]] [[chunk 235]]

    Specialty agent PA/QL/LA conditions

    Coverage and utilization management for specialty and high-cost agents:

    Specialty agent coverage conditions: Specialty and high-cost agents are covered when listed on the formulary but commonly require prior authorization (PA), are subject to specific quantity limits (QL), and sometimes have Limited Availability (LA) or site-of-care designations; manufacturers' packaging QLs apply as listed.see per-drug QL values

    Examples: CF agents, pulmonary hypertension agents, pulmonary fibrosis agents (chunks 262–265).

    Ophthalmic ST/QL

    Utilization controls for ophthalmic anti-inflammatories:

    Ophthalmic ST/QL: Certain ophthalmic anti-inflammatory agents require step therapy (ST) or have quantity limits (QL).Per-agent QL as listed

    Examples: difluprednate and loteprednol are listed with ST; ketorolac 0.5% has QL 20 ML per 30 days (chunks 254–255).

    Excluded drugs (abbreviated ED) are not normally covered under a Medicare Prescription Drug Plan. Amounts members pay for an ED do not count toward total drug costs (for example, they do not help a member qualify for catastrophic coverage), and members receiving extra help will generally not receive additional subsidies for these drugs. Coverage for excluded drugs may be available only on specific Priority Medicare offerings (for example, Priority Medicare® Thrive and Priority Medicare® Thrive Plus).

    Formulary entries flagged NE (No Express Scripts) or ED (Excluded Drug) indicate restricted dispensing or lack of coverage through Express Scripts home delivery or exclusion from normal Part D coverage; check the line‑item entry for the specific product. Specialty drugs assigned to Tier 5 are managed with utilization controls shown in the Requirements/Limits column — e.g., many Tier 5 agents require PA (prior authorization) and often carry QL (quantity limits). Examples in this formulary include AUVELITY and EXXUA (Tier 5; PA; QL) and DIFICID products which carry ST (step therapy) plus QL entries.

    Specialty medications listed as Tier 5 are subject to a supply limitation of a 30‑day supply only. This supply rule is noted in the formulary legend and is applied to Tier 5 entries throughout the drug list; confirm the per‑product QL where a specific quantity limit is provided.

    Formulary Listings & Coding / Quantity Examples

    Selected formulary-listed drugs with restrictions/tiersmixed
    fentanyl transdermal patch 72 hour 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hrfentanyl transdermal patch 72 hour — listed with tier and QL
    lidocaine external patch 5%lidocaine external patch 5% — PA; QL (90 EA per 30 days)
    KLOXXADOOpioid reversal agent — QL (2 EA per 30 days)
    ARIKAYCEARIKAYCE — Tier 5; PA; QL (235.2 ML per 28 days)
    XIFAXAN ORAL TABLET 200 MGPA; QL (9 EA per 30 days)
    XIFAXAN ORAL TABLET 550 MGPA; QL (60 EA per 30 days)
    Formulary entries (no billing codes provided in this segment)mixed
    No codes listed
    Selected formulary drug entries (examples)mixed
    AUVELITYAUVELITY — Tier 5; Requirements/Limits = PA; QL (60 EA per 30 days); NE
    EXXUAEXXUA — Tier 5; Requirements/Limits = PA; QL (30 EA per 30 days)
    ZURZUVAE ORAL CAPSULE 20 MG/25 MG/30 MGZURZUVAE ORAL CAPSULE 20 MG/25 MG/30 MG — Tier 5; Requirements/Limits = PA; QL (28 EA per 365 days for 20/25 mg; 14 EA per 365 days for 30 mg)
    EMSAMEMSAM — Tier 5; Requirements/Limits = PA
    MARPLANMARPLAN — Tier 4; Requirements/Limits = PA; QL (180 EA per 30 days)
    DRIZALMADRIZALMA SPRINKLE ORAL CAPSULE DR 20/30 MG — Tier 4; Requirements/Limits = PA; QL (60 EA per 30 days)
    FETZIMAFETZIMA — Tier 4; Requirements/Limits = ST; QL (30 EA per 30 days); NE
    TRINTELLIXTRINTELLIX — Tier 4; Requirements/Limits = ST; QL (30 EA per 30 days); NE
    Sample Quantity Limits listedmixed
    QL (49 EA per 28 days)Quantity limit for KISQALI FEMARA (200 MG DOSE)
    QL (70 EA per 28 days)Quantity limit for KISQALI FEMARA (400 MG DOSE)
    QL (91 EA per 28 days)Quantity limit for KISQALI FEMARA (600 MG DOSE)
    XPOVIO quantity limitsmixed
    QL (8 EA per 28 days)Quantity limit example for XPOVIO (100 mg once weekly) pack
    QL (16 EA per 28 days)Quantity limit example for XPOVIO (40 mg once weekly) pack
    VITRAKVI quantity limitsmixed
    QL (60 EA per 30 days)Quantity limit example for VITRAKVI 100 mg
    QL (90 EA per 30 days)Quantity limit example for VITRAKVI 25 mg
    Formulary drug listings (partial, as presented in this segment)mixed
    ZYKADIAZYKADIA ORAL TABLET (Tier 5) - PA
    bexarotene externalbexarotene external (Tier 5) - PA; QL (60 GM per 30 days)
    bexarotene oralbexarotene oral (Tier 5) - PA
    tretinoin oraltretinoin oral (Tier 5) - PA
    leucovorin calcium oralleucovorin calcium oral (Tier 2)
    mesna oralmesna oral (Tier 4)
    albendazole oralalbendazole oral (Tier 4)
    ivermectin oral tablet 3 mgivermectin oral tablet 3 mg (Tier 3)
    COARTEMCOARTEM (Tier 4) - QL (24 EA per 30 days)
    IMPAVIDOIMPAVIDO (Tier 5) - PA; QL (84 EA per 28 days)
    1–10 of 41
    1/5
    Formulary units/abbreviationsmixed
    EAEach (unit used in quantity limits)
    MLMilliliters (unit used in quantity limits)
    Formulary control codes and examplesmixed
    QL (15 ML per 25 days)SOLIQUA quantity limit
    QL (60 EA per 30 days)dabigatran etexilate mesylate quantity limit example
    QL (74 EA per 30 days)ELIQUIS DVT/PE starter pack quantity limit
    QL (620 ML per 30 days)XARELTO oral suspension recon. quantity limit
    PAPrior Authorization flag (applies to multiple items e.g., novofine pen needle, NIVESTYM)
    B/DPart B vs Part D billing designation (applies to products like PROCRIT certain strengths)
    Coding — none providedneutral
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes provided in this segment; only medication names, strengths, tiers, and requirements are listed.
    Formulary drug lines (sample from this segment)mixed
    methylphenidate hcl er (osm) oral tablet extended release 18 mgDrug Tier = 4; QL (30 EA per 30 days)
    methylphenidate hcl er (osm) oral tablet extended release 54 mgDrug Tier = 4; QL (30 EA per 30 days)
    methylphenidate hcl er oral tablet extended release 27 mgDrug Tier = 4; QL (60 EA per 30 days)
    methylphenidate hcl oral solution 10 mg/5mlDrug Tier = 4; QL (1500 ML per 30 days)
    AUSTEDO ORAL TABLET 12 MG, 9 MGDrug Tier = 4; Requirements/Limits = PA; QL (120 EA per 30 days)
    AUSTEDO ORAL TABLET 6 MGDrug Tier = 4; Requirements/Limits = PA; QL (60 EA per 30 days)
    AUSTEDO XRDrug Tier = 4; Requirements/Limits = PA; QL (30 EA per 30 days)
    EVRYSDI ORAL TABLETDrug Tier = 5; Requirements/Limits = PA; QL (30 EA per 30 days)
    tetrabenazine oral tablet 12.5 mgDrug Tier = 4; Requirements/Limits = PA; QL (90 EA per 30 days)
    tetrabenazine oral tablet 25 mgDrug Tier = 5; Requirements/Limits = PA; QL (120 EA per 30 days)
    1–10 of 28
    1/3
    NDC/CPT/HCPCS codesmixed
    No codes listed
    Formulary requirement codesmixed
    QL (8 ML per 28 days)Quantity limit example for COSENTYX, ENBREL and others as listed
    QL (3.42 ML per 30 days)Quantity limit for certain DUPIXENT presentations
    QL (1.34 ML per 30 days)Quantity limit for DUPIXENT 100 mg prefilled syringe
    QL (0.5 ML per 28 days)Quantity limit for SELARSDI / YESINTEK 45 mg
    QL (1 ML per 28 days)Quantity limit for SELARSDI 90 mg
    PAPrior authorization required (multiple listed agents)
    B/DPart B vs. Part D designation (used for some agents)
    Formulary items (no CPT/HCPCS/ICD codes provided)mixed
    No codes listed
    Listed drugs (selected examples from chunks)mixed
    AZASITEAZASITE (ophthalmic)
    NATACYNNATACYN (ophthalmic)
    ZIRGANZIRGAN (ophthalmic)
    ALPHAGAN PALPHAGAN P OPHTHALMIC SOLUTION 0.1%
    COMBIGANCOMBIGAN
    SIMBRINZASIMBRINZA
    CAYSTONCAYSTON (CF agent)
    KALYDECOKALYDECO (CF agent)
    ORKAMBIORKAMBI
    PULMOZYMEPULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML
    1–10 of 19
    1/2
    Quantity limits (formulary notation)mixed
    QL (example)Quantity limit examples such as 'QL (30 ML per 30 days)', 'QL (21 GM per 30 days)', 'QL (60 EA per 30 days)'
    Common quantity limits — examples: pregabalin and other QLs
    Common QL: pregabalin 25–200 mgPregabalin oral capsules 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg — QL 90 EA per 30 days (Tier 3)
    Common QL: pregabalin 225–300 mgPregabalin oral capsules 225 mg, 300 mg — QL 60 EA per 30 days (Tier 3)
    Common QL: typical EA limitsExamples include QL 90 EA per 30 days; QL 60 EA per 30 days — used across multiple oral solid products
    Common QL: ML/GM limitsExamples include QL 235.2 ML per 28 days (ARIKAYCE), QL 750 ML per 30 days (diclofenac sodium external) and other ML/GM units
    Tier/supply noteTier 5 (Specialty) drugs are limited to a 30‑day supply (applies to many entries with QL shown)
    Quantity Limits examples — selected suspension, solution, and capsule QLs
    DIFICID QL examplesDIFICID oral suspension (reconstituted) — QL 136 mL per 10 days; DIFICID oral tablet — QL 20 EA per 10 days
    brivaracetam QL examplesBrivaracetam oral solution — QL 600 mL per 30 days; brivaracetam oral tablet — QL 60 EA per 30 days
    Pregabalin capsule strengths consolidationPregabalin oral capsule strengths listed: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg (QL 90 EA/30 days) and 225 mg, 300 mg (QL 60 EA/30 days)
    Quantity limits examples — selected high‑tier drugs and specialty antineoplastics
    High‑tier QLs (examples)AUVELITY — QL 60 EA per 30 days; EXXUA — QL 30 EA per 30 days; MARPLAN — QL 180 EA per 30 days; FETZIMA — QL 30 EA per 30 days
    Specialty antineoplastics and QLsMany specialty antineoplastics and high‑cost agents list PA and product‑specific QLs (varies by agent and strength)
    Pregabalin strengths notedPregabalin oral capsule strengths explicitly listed in the formulary: 25, 50, 75, 100, 150, 200, 225, 300 mg — associated QLs per strength as above
    Quantity limit examples — varies by drug and strength
    Variable QLs by strength/formulationQuantity limits vary by drug and strength (examples: 49 EA per 28 days up to 240 EA per 30 days for certain oncology tablets)
    XPOVIO examplesXPOVIO therapy packs have QLs expressed per pack/28 days (examples: QL 8 EA per 28 days; QL 16 EA per 28 days depending on pack)
    Pregabalin strength consolidationPregabalin oral capsules listed across strengths 25–300 mg with QLs: 25–200 mg QL 90 EA/30 days; 225–300 mg QL 60 EA/30 days
    Quantity limits examples — ML/GM and oral solution/tablet limits
    ML/GM QL examplesExamples include bexarotene external QL 60 GM per 30 days; INVEGA HAFYERA QL 3.5 mL per 180 days (1092 mg/3.5 mL strength) and other ML QLs
    Oral solution/tablet QLsAripiprazole oral solution QL 750 mL per 30 days; OPIPZA oral film QLs vary by strength (e.g., 30–120 EA per 30 days)
    Pregabalin capsule full listPregabalin oral capsule strengths included in formulary: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg — QL values specified per strength groups (90 EA/30 days and 60 EA/30 days)

    Prescriber Requirements, Prior Authorization & Step Therapy

    Prior Authorization

    Obtain PA and document B/D setting

    Certain drugs require prior authorization and some may have Part B vs Part D (B/D) billing considerations; prescribers must submit documentation of the drug's use and setting to determine benefit routing and obtain PA before the prescription is filled to ensure coverage. Failure to obtain PA may result in noncoverage.

    • Prescriber must submit information describing drug use/setting for B/D determination (chunk 18).
    • Obtain prior authorization before filling; lack of PA may result in noncoverage (chunk 12, 21).
    Prior Authorization

    Prior authorization required before dispensing

    Priority Health Medicare requires prior authorization for many listed drugs — prescribers must obtain PA approval before the prescription is filled to avoid denial or noncoverage.

    • PA flag appears next to numerous specialty and Tier 4–5 agents; submit PA per plan procedures (chunks 21, 90).
    • If PA is not obtained, the drug may not be covered (chunk 12).
    Prior Authorization

    Get PA for specialty/injectable and HI drugs

    Select specialty/injectable agents and some home-infusion products are subject to prior authorization and/or home infusion channel requirements; obtain PA and route claims per the HI designation when applicable.

    • Examples include ARIKAYCE and other IV/infusion antibiotics that have PA and HI flags (chunks 50, 52).
    • Home infusion designation (HI) may require billing under medical benefit and appropriate authorization (chunk 50).
    Prior Authorization

    PA + QL for lidocaine 5% patch (90 EA/30 days)

    Lidocaine external patch 5% requires prior authorization and is limited to 90 each per 30 days; do not exceed the listed quantity without prior approval.

    • Lidocaine external patch 5% — Requirements/Limits = PA; QL (90 EA per 30 days) (chunk 45).
    Prior Authorization

    Submit PA for listed specialty/high‑tier agents

    Certain specialty or high-tier drugs are marked 'PA' and require prior authorization; prescribers must submit PA documentation for those agents (examples include brivaracetam, EPIDIOLEX, FINTEPLA, and selected XCOPRI presentations).

    • Brivaracetam oral solution/tablet — PA; QL (600 mL / 60 EA per 30 days) (chunk 63).
    • EPIDIOLEX and FINTEPLA are listed with PA and QL requirements (chunk 63).
    Prior Authorization

    PA required for many Tier‑4/5 drugs

    Multiple Tier‑4 and Tier‑5 drugs are annotated with 'PA' in the Requirements/Limits column; obtain prior authorization for listed agents such as AUVELITY, EXXUA, ZURZUVAE, EMSAM, MARPLAN, DRIZALMA, CRESEMBA and numerous antineoplastics before coverage is approved.

    • AUVELITY, EXXUA, ZURZUVAE — Requirements/Limits = PA (chunk 72).
    • Many antineoplastics (e.g., STIVARGA, VITRAKVI, KISQALI FEMARA) are marked PA; submit PA as required (chunks 105, 90).
    Prior Authorization

    Obtain PA for specialty formulary entries

    PA appears next to most specialty drug entries; providers must obtain prior authorization for those drugs to secure coverage.

    • Claims for listed specialty drugs may be denied or require review if PA is not obtained (chunk 90).
    • Many oncology and specialty oral agents list PA and QL (chunk 105).
    Prior Authorization

    PA required for listed PA drugs (brands/specialty)

    Many specialty and brand drugs in the formulary list 'PA' — providers must obtain prior authorization before coverage will be approved for these line‑items (examples include ZYKADIA, CAPLYTA, VERSACLOZ, NUPLAZID).

    • ZYKADIA and multiple retinoids/oncology agents are PA‑designated (chunk 108).
    • Aripiprazole oral solution and other psychiatric specialty products show PA and QL expectations (chunk 114).
    Prior Authorization

    PA applies to GLP‑1 and insulin supplies

    Certain products (including some GLP‑1 agents and insulin supplies) require prior authorization; follow PA procedures for products such as MOUNJARO, OZEMPIC, RYBELSUS and listed insulin supplies.

    • MOUNJARO — Requirements = PA; QL (2 mL per 28 days) (chunk 137).
    • OZEMPIC — Requirements = PA; QL (3 mL per 28 days) for certain formulations (chunk 138).
    • Insulin supplies/pen needles are marked PA per entries (chunk 141).
    Prior Authorization

    PA required for selected specialty/brand drugs

    Some listed specialty/brand agents (e.g., REPATHA, REPATHA PUSHTRONEX, ENTRESTO formulations, NEXLETOL/NEXLIZET) require prior authorization; submit PA per plan instructions to avoid denial.

    • REPATHA products have QL and are PA‑designated depending on formulation (chunk 175).
    • Multiple cardiovascular and neuromuscular specialty agents list PA (chunk 181).
    Prior Authorization

    Submit PA for numerous specialty agents

    Numerous drugs — including AUSTEDO, AVONEX formulations, fingolimod, glatiramer products, EBGLYSS, OTEZLA and tolvaptan — are marked 'PA' and require prior authorization; providers must submit PA to obtain coverage.

    • AUSTEDO entries show Requirements/Limits = PA and QL (chunk 181).
    • Tolvaptan is marked PA with QL (120 EA per 30 days) in oncology/pulmonary listings (chunks 182, 199).
    Prior Authorization

    PA required for many specialty injectables

    Multiple specialty and high‑cost injectables are designated 'PA' — obtain prior authorization for products such as COSENTYX, DUPIXENT, SKYRIZI, TAVNEOS, XOLAIR, ENBREL and related biologics before dispensing.

    • COSENTYX, DUPIXENT, SKYRIZI show PA and specified QLs (chunk 228‑230).
    • ENBREL and adalimumab presentations are PA‑designated with QL examples provided (chunk 235).
    Prior Authorization

    Obtain PA for listed specialty/brand products

    Many specialty and select brand products list 'PA' in the formulary; providers must request and receive prior authorization for those agents (see line‑item entries listing 'PA').

    • Adalimumab‑adaz and HUMIRA/HADLIMA formulations list PA and QL per presentation (chunks 234‑236).
    • Follow the PA submission process for these products to secure coverage (chunk 235).
    Prior Authorization

    PA (± QL/LA) for selected specialty agents

    Certain cystic fibrosis, pulmonary hypertension, and pulmonary fibrosis agents are subject to prior authorization and may also have quantity limits or limited availability; submit PA and any required QL documentation for coverage.

    • CF agents (e.g., TRIKAFTA) and ORKAMBI show PA/QL designations (chunk 263).
    • Pulmonary fibrosis agents like pirfenidone are PA‑designated with QLs (chunk 266 referenced in inventory).
    Step Therapy

    Follow Step Therapy and document prior trials

    Step therapy may require trying specified alternative drugs first before covering another drug for the same condition; providers must document trial and failure or intolerance when requesting coverage for the next‑line therapy.

    • Step therapy requires trial of first‑line agent(s) before covering alternatives; documentation of failure/intolerance is expected (chunks 12, 21).
    • DIFICID and select antidepressants/antineoplastics list ST as a requirement where indicated (formulary entries).
    Step Therapy

    Document required step therapy completion

    Step therapy is referenced across the formulary legend and specific entries; when a drug lists 'ST' the provider must ensure documented completion or failure of required steps before coverage will be approved.

    • Selected drugs (e.g., DIFICID) require ST prior to coverage (chunk 59).
    • FETZIMA, TRINTELLIX and other agents are listed with 'ST' indicating step therapy must be satisfied (chunk 72, 74).

    Per-Drug Quantity Limits (Selected Examples)

    XARELTO 10MG (example)
    XARELTO 10 mg (example)30 tablets per prescription (quantity limit example cited in restrictions overview).
    Supply noteQuantity limits may be expressed per prescription or per days (e.g., per 30 days).
    PA impactSome QLs are enforced in addition to prior authorization requirements; failure to follow may result in noncoverage.
    Selected QLs — analgesics and topical analgesics
    diclofenac sodium external solution 1.5%QL 750 ML per 30 days
    fentanyl transdermal patch (various strengths)QL 10 EA per 30 days
    hydromorphone HCl ER oral tablet (24 hr)QL 60 EA per 30 days
    Opioid ER quantity limits
    hydromorphone HCl ER oral tablet (extended release)QL 60 EA per 30 days
    oxymorphone HCl oral tablet 10 mgQL 360 EA per 30 days
    morphine sulfate ER examplesQLs vary by strength (e.g., 60 EA, 120 EA per 30 days depending on strength)
    Opioid reversal agents — quantity limits
    KLOXXADOQL 2 EA per 30 days
    Naloxone injection solutionsVarious QLs depending on presentation; KLOXXADO listed specifically
    Opioid reversal QL impactQuantity limits for reversal agents are enforced and may affect coverage frequency
    ARIKAYCE and selected antibacterial QLs
    ARIKAYCEQL 235.2 ML per 28 days
    Linezolid (various IV/oral forms)Linezolid oral tablet QL 56 EA per 28 days; IV forms listed with HI where applicable
    Vancomycin oral capsule125 mg QL 80 EA per 30 days; 250 mg QL 160 EA per 30 days
    Linezolid and vancomycin oral capsule QLs
    linezolid oral tabletQL 56 EA per 28 days
    vancomycin oral capsule 125 mgQL 80 EA per 30 days
    vancomycin oral capsule 250 mgQL 160 EA per 30 days
    Vancomycin oral capsule QLs
    vancomycin oral capsule 125 mgQL 80 EA per 30 days
    vancomycin oral capsule 250 mgQL 160 EA per 30 days
    Vancomycin oral solutionVarious reconstituted presentations listed; QLs vary by formulation
    Selected specialty psychiatric agent QLs
    AUVELITYQL 60 EA per 30 days; Requirements = PA; NE flag present
    EXXUAQL 30 EA per 30 days; Requirements = PA
    INVEGA HAFYERA (example)QL 3.5 ML per 180 days for 1092 mg/3.5 mL presentation
    EXXUA and related antidepressant QLs
    EXXUAQL 30 EA per 30 days; Requirements = PA
    AUVELITYQL 60 EA per 30 days; Requirements = PA; NE flag
    FETZIMAQL 30 EA per 30 days; Requirements = ST
    FETZIMA, TRINTELLIX, OPIPZA — QLs and ST/PA
    FETZIMAQL 30 EA per 30 days; Requirements = ST
    TRINTELLIXQL 30 EA per 30 days (listed with ST for some entries)
    OPIPZA (examples)OPIPZA ORAL FILM entries show PA and QLs varying by strength (30–120 EA per 30 days)
    VITRAKVI quantity limits
    VITRAKVI ORAL SOLUTIONQL 300 mL per 30 days (PA applies)
    VITRAKVI ORAL CAPSULE 100 mgQL 60 EA per 30 days (PA applies)
    VITRAKVI ORAL CAPSULE 25 mgQL 90 EA per 30 days (PA applies)
    Aripiprazole formulations — QLs
    aripiprazole oral solutionQL 750 mL per 30 days; Requirements = PA
    aripiprazole oral tabletQL 30 EA per 30 days for some formulations
    ABILIFY MAINTENA injectableQL 1 EA per 30 days (injectable forms have separate ML/EA QLs)
    INVEGA product quantity limits (examples)
    INVEGA HAFYERA examplesQL 3.5 ML per 180 days and QL 5 ML per 180 days depending on strength
    INVEGA SUSTENNA examplesQL values per 30 days vary by strength (e.g., 0.25–1.5 mL per 30 days)
    Paliperidone ER tabletsSome ER oral paliperidone entries include ST and QL (30–60 EA per 30 days)
    INTELENCE and HIV regimen QLs
    INTELENCE ORAL TABLET 25 MG (etravirine)QL 120 EA per 30 days
    efavirenz oral tabletListed with tier; QL where shown in individual entries
    HIV regimen agents (general)Many HIV agents show QLs such as 30 EA per 30 days for combination products
    PAXLOVID quantity limits
    PAXLOVID (150/100)QL 40 EA per 180 days (other formulations have different QLs)
    PAXLOVID (300/100 & 150/100)Example entries show QL 22 EA per 180 days and QL 60 EA per 180 days depending on pack/formulation
    Formulation-specific QLsPAXLOVID QLs vary by pack size and formulation as shown in listings
    XARELTO oral tablet/suspension QLs
    XARELTO oral tablet 10/20 mgQL 30 EA per 30 days (listed as supply limit)
    XARELTO oral suspension (reconstituted)QL 620 ML per 30 days
    XARELTO starter packsStarter packs show distinct QLs (e.g., 51 EA per 30 days)
    REPATHA product quantity limits
    REPATHA (various presentations)QL 2 mL per 28 days for some presentations; REPATHA PUSHTRONEX QL 3.5 mL per 30 days (PA applies)
    REPATHA SURECLICKQL 2 mL per 28 days (PA applies)
    PUSHTRONEX formulation noteSome REPATHA formulations have different per-period ML limits depending on device
    Biologic/specialty injectable QL examples
    Examples across biologic injectablesQuantity limits expressed in mL: e.g., 8 ML per 28 days; 3.42 ML per 30 days; 1.2 ML per 56 days
    COSENTYX examplesQL 8 ML per 28 days or 2 ML per 28 days depending on presentation
    DUPIXENT examplesQLs include 3.42 ML per 30 days and 1.34 ML per 30 days for specific syringe presentations

    Home Infusion, Infusion Center & Billing (Part B vs D)

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations, Tier Definitions & Terms

    Transition and Continuation Rules

    Transition supply

    Transition and temporary supply rules

    Transition supply for members: Members may receive a transition supply of at least 30 days of medication when experiencing a level-of-care change or when first joining the plan; long-term care residents may receive a 31-day emergency supply while pursuing an exception.30 days (or 31 days for LTC emergency)

    [[chunk 15]] [[chunk 6]]

    Step Therapy Rules & Examples

    StepRequirementNotes
    1
    Must try specified first-line drugs before escalation to alternative therapies.
    If initial required drug does not work or is not tolerated, documentation may be required to allow coverage of the next-line agent.
    Agent / ClassRequirementQuantity Limit (as listed)
    DIFICID oral suspension
    ST (Step Therapy) required prior to coverage
    QL (136 mL per 10 days)
    DIFICID oral tablet
    ST (Step Therapy) required prior to coverage
    QL (20 EA per 10 days)
    AgentRequirementQuantity Limit / Notes
    FETZIMA
    ST (Step Therapy)
    QL (30 EA per 30 days); NE flag noted
    TRINTELLIX
    ST (Step Therapy)
    QL (30 EA per 30 days)
    vilazodone
    ST (Step Therapy)
    (listed with ST in formulary entries)
    eletriptan
    ST (Step Therapy)
    (antimigraine agents include ST flags where indicated)
    AgentRequirementNotes
    travoprost (bak-free)
    ST (Step Therapy) applies
    Listed in ophthalmic agents with ST flag (Tier 3)
    Agent / FormulationRequirementQuantity Limit / Notes
    difluprednate (ophthalmic)
    ST (Step Therapy) required
    Listed under Ophthalmic Anti-Inflammatories with ST; QLs vary by formulation where shown
    loteprednol etabonate ophthalmic gel / suspension
    ST (Step Therapy) required
    Listed with ST; specific QL not shown in this excerpt

    Background & Policy Scope

    Biological products are complex medicines distinct from typical small‑molecule drugs; they may have biosimilar alternatives rather than conventional generics. Some biosimilars are designated as interchangeable under state law and may be substituted without a new prescription where allowed. The formulary groups biologic and other agents by therapeutic class and provides abbreviation definitions (for example PA, QL, ED, HI) to guide coverage and dispensing rules.